COGT
Price
$7.00
Change
-$0.53 (-7.04%)
Updated
Mar 3 closing price
Capitalization
857.29M
70 days until earnings call
FATE
Price
$1.03
Change
-$0.09 (-8.04%)
Updated
Mar 3 closing price
Capitalization
127.56M
57 days until earnings call
Ad is loading...

COGT vs FATE

Header iconCOGT vs FATE Comparison
Open Charts COGT vs FATEBanner chart's image
Cogent Biosciences
Price$7.00
Change-$0.53 (-7.04%)
Volume$1.49M
Capitalization857.29M
Fate Therapeutics
Price$1.03
Change-$0.09 (-8.04%)
Volume$3.84M
Capitalization127.56M
COGT vs FATE Comparison Chart
Loading...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COGT vs. FATE commentary
Mar 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COGT is a StrongBuy and FATE is a Buy.

Ad is loading...
COMPARISON
Comparison
Mar 04, 2025
Stock price -- (COGT: $7.00 vs. FATE: $1.03)
Brand notoriety: COGT and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COGT: 100% vs. FATE: 150%
Market capitalization -- COGT: $857.29M vs. FATE: $127.56M
COGT [@Biotechnology] is valued at $857.29M. FATE’s [@Biotechnology] market capitalization is $127.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $398.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.48B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COGT’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • COGT’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than COGT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COGT’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 3 bullish TA indicator(s).

  • COGT’s TA Score: 4 bullish, 6 bearish.
  • FATE’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, COGT is a better buy in the short-term than FATE.

Price Growth

COGT (@Biotechnology) experienced а -6.17% price change this week, while FATE (@Biotechnology) price change was -23.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.44%. For the same industry, the average monthly price growth was -9.63%, and the average quarterly price growth was -4.94%.

Reported Earning Dates

COGT is expected to report earnings on May 13, 2025.

FATE is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-5.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COGT($857M) has a higher market cap than FATE($128M). COGT YTD gains are higher at: -10.256 vs. FATE (-37.273). FATE has higher annual earnings (EBITDA): -177.57M vs. COGT (-256.4M). COGT has more cash in the bank: 336M vs. FATE (297M). COGT has less debt than FATE: COGT (17.8M) vs FATE (99M). FATE has higher revenues than COGT: FATE (13.4M) vs COGT (0).
COGTFATECOGT / FATE
Capitalization857M128M670%
EBITDA-256.4M-177.57M144%
Gain YTD-10.256-37.27328%
P/E RatioN/AN/A-
Revenue013.4M-
Total Cash336M297M113%
Total Debt17.8M99M18%
FUNDAMENTALS RATINGS
COGT vs FATE: Fundamental Ratings
COGT
FATE
OUTLOOK RATING
1..100
5877
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
68100
SMR RATING
1..100
9694
PRICE GROWTH RATING
1..100
6596
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (14) in the Biotechnology industry is significantly better than the same rating for COGT (82) in the Miscellaneous industry. This means that FATE’s stock grew significantly faster than COGT’s over the last 12 months.

COGT's Profit vs Risk Rating (68) in the Miscellaneous industry is in the same range as FATE (100) in the Biotechnology industry. This means that COGT’s stock grew similarly to FATE’s over the last 12 months.

FATE's SMR Rating (94) in the Biotechnology industry is in the same range as COGT (96) in the Miscellaneous industry. This means that FATE’s stock grew similarly to COGT’s over the last 12 months.

COGT's Price Growth Rating (65) in the Miscellaneous industry is in the same range as FATE (96) in the Biotechnology industry. This means that COGT’s stock grew similarly to FATE’s over the last 12 months.

COGT's P/E Growth Rating (100) in the Miscellaneous industry is in the same range as FATE (100) in the Biotechnology industry. This means that COGT’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COGTFATE
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 13 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
89%
View a ticker or compare two or three
Ad is loading...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYCIX150.92N/A
N/A
Rydex Consumer Products Inv
MIGBX32.27N/A
N/A
MFS Massachusetts Inv Gr Stk B
NEAGX44.71N/A
N/A
Needham Aggressive Growth Retail
PGPRX25.74N/A
N/A
George Putnam Balanced R
NMUEX10.36N/A
N/A
Neuberger Berman Multi-Cap Opp E

COGT and

Correlation & Price change

A.I.dvisor indicates that over the last year, COGT has been loosely correlated with SPHDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COGT jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COGT
1D Price
Change %
COGT100%
-7.04%
SPHDF - COGT
63%
Loosely correlated
N/A
ENGN - COGT
47%
Loosely correlated
-3.66%
ARWR - COGT
41%
Loosely correlated
-6.29%
FATE - COGT
41%
Loosely correlated
-7.59%
SLNO - COGT
40%
Loosely correlated
-6.17%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-7.59%
ALLO - FATE
57%
Loosely correlated
-7.69%
NTLA - FATE
55%
Loosely correlated
-6.34%
NKTX - FATE
54%
Loosely correlated
-6.86%
RCKT - FATE
53%
Loosely correlated
-6.98%
CRSP - FATE
53%
Loosely correlated
-3.71%
More